RT Journal Article
SR Electronic
T1 The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.03.21268111
DO 10.1101/2022.01.03.21268111
A1 Brian J. Willett
A1 Joe Grove
A1 Oscar A. MacLean
A1 Craig Wilkie
A1 Nicola Logan
A1 Giuditta De Lorenzo
A1 Wilhelm Furnon
A1 Sam Scott
A1 Maria Manali
A1 Agnieszka Szemiel
A1 Shirin Ashraf
A1 Elen Vink
A1 William T. Harvey
A1 Chris Davis
A1 Richard Orton
A1 Joseph Hughes
A1 Poppy Holland
A1 Vanessa Silva
A1 David Pascall
A1 Kathryn Puxty
A1 Ana da Silva Filipe
A1 Gonzalo Yebra
A1 Sharif Shaaban
A1 Matthew T. G. Holden
A1 Rute Maria Pinto
A1 Rory Gunson
A1 Kate Templeton
A1 Pablo R. Murcia
A1 Arvind H. Patel
A1 The COVID-19 Genomics UK (COG-UK) Consortium
A1 John Haughney
A1 David L. Robertson
A1 Massimo Palmarini
A1 Surajit Ray
A1 Emma C. Thomson
YR 2022
UL http://medrxiv.org/content/early/2022/01/26/2022.01.03.21268111.abstract
AB Vaccines based on the spike protein of SARS-CoV-2 are a cornerstone of the public health response to COVID-19. The emergence of hypermutated, increasingly transmissible variants of concern (VOCs) threaten this strategy. Omicron, the fifth VOC to be described, harbours 30 amino acid mutations in spike including 15 in the receptor-binding domain. Here, we demonstrate substantial evasion of neutralisation by Omicron in vitro using sera from vaccinated individuals. Importantly, these data are mirrored by a substantial reduction in real-world vaccine effectiveness that is partially restored by booster vaccination. We also demonstrate that Omicron does not induce cell syncytia and favours a TMPRSS2-independent endosomal entry pathway. Such marked changes in antigenicity and replicative biology may underlie the rapid global spread and altered pathogenicity of the Omicron variant.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe EVADE study is supported by HDR-UK (E.C.T). COG-UK is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) [grant code: MC_PC_19027], and Genome Research Limited, operating as the Wellcome Sanger Institute (G.M., R.M.B., D.L.R., E.C.T.). The COVID-19 DeplOyed VaccinE (DOVE) study is funded by the Medical Research Council core award (MCUU1201412) and COG-UK. We acknowledge the support of the G2P-UK National Virology Consortium (MR/W005611/1) funded by the UKRI (M.P.,E.C.T.). A.F., J.H., R.O and D.L.R acknowledge the MRC (MC_UU_12014/12) and DLR the Wellcome Trust (220977/Z/20/Z). W.T.H. is funded by the MRC (MR/R024758/1 and MR/W005611/1). N.L. and B.J.W. were funded by the Biotechnology and Biological Sciences Research Council (BBSRC, BB/R004250/1), G.T. was funded by the Department of Health and Social Care (DHSC, BB/R019843/1). J.G. is supported by a Sir Henry Dale Fellowship from the Wellcome Trust and Royal Society (107653/Z/15/A) and by the Medical Research Council (MC_UU_12014). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The North West Central Liverpool Research Ethics Committee/IRB gave ethical approval for the DOVE study (21/NW/0073). Informed written consent was obtained for all participants. In addition, the NHS GG&C SafeHaven gave derogated ethical approval for the use of anonymised population data (GSH/21/IM/001). NHS Caldicott approval was also obtained for the use of anonymised clinical data. Lothian biorepository ethical approval was given for the isolation of virus from clinical samples (reference 10/S1402/33). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll sequence data are published via GISAID. All data produced in the present study are available upon reasonable request to the authors other than identifying clinical information.